Movement Alert｜Novartis Rises 3.76% in Regular Trading, Q2 Earnings Significantly Beat Expectations Signaling Growth Recovery

Market Focus07-21

On July 21, Novartis rose 3.76% in regular trading, trading at $154.1/share, with turnover of $79.53 million. The rally was driven by the company's Q2 earnings release that significantly exceeded market expectations.

Novartis reported Q2 adjusted earnings per share of $2.41, beating the consensus estimate of $2.13 by approximately 13%. Net sales came in at $14.408 billion, surpassing the expected $14.0 billion. Notably, Q1 results had disappointed due to generic competition against its blockbuster heart drug Entresto, but strong performance from next-generation oncology drugs successfully offset the generic impact this quarter, signaling a return to growth trajectory.

Additionally, Novartis CEO stated the company will continue pursuing acquisitions, particularly targeting deals under $2 billion while not ruling out larger transactions. The company also expects multiple key clinical data readouts in the second half, covering cardiology and multiple sclerosis, including del-desiran for muscular disease acquired through its $12 billion Avidity Biosciences deal.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101227232?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 21:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101227232","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Novartis Rises 3.76% in Regular Trading, Q2 Earnings Significantly Beat Expectations Signaling Growth Recovery","media":"Market Focus","content":"<p><p>On July 21, Novartis rose 3.76% in regular trading, trading at $154.1/share, with turnover of $79.53 million. The rally was driven by the company's Q2 earnings release that significantly exceeded market expectations.</p><p>Novartis reported Q2 adjusted earnings per share of $2.41, beating the consensus estimate of $2.13 by approximately 13%. Net sales came in at $14.408 billion, surpassing the expected $14.0 billion. Notably, Q1 results had disappointed due to generic competition against its blockbuster heart drug Entresto, but strong performance from next-generation oncology drugs successfully offset the generic impact this quarter, signaling a return to growth trajectory.</p><p>Additionally, Novartis CEO stated the company will continue pursuing acquisitions, particularly targeting deals under $2 billion while not ruling out larger transactions. The company also expects multiple key clinical data readouts in the second half, covering cardiology and multiple sclerosis, including del-desiran for muscular disease acquired through its $12 billion Avidity Biosciences deal.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Novartis Rises 3.76% in Regular Trading, Q2 Earnings Significantly Beat Expectations Signaling Growth Recovery</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Novartis Rises 3.76% in Regular Trading, Q2 Earnings Significantly Beat Expectations Signaling Growth Recovery\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-21 21:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 21, Novartis rose 3.76% in regular trading, trading at $154.1/share, with turnover of $79.53 million. The rally was driven by the company's Q2 earnings release that significantly exceeded market expectations.</p><p>Novartis reported Q2 adjusted earnings per share of $2.41, beating the consensus estimate of $2.13 by approximately 13%. Net sales came in at $14.408 billion, surpassing the expected $14.0 billion. Notably, Q1 results had disappointed due to generic competition against its blockbuster heart drug Entresto, but strong performance from next-generation oncology drugs successfully offset the generic impact this quarter, signaling a return to growth trajectory.</p><p>Additionally, Novartis CEO stated the company will continue pursuing acquisitions, particularly targeting deals under $2 billion while not ruling out larger transactions. The company also expects multiple key clinical data readouts in the second half, covering cardiology and multiple sclerosis, including del-desiran for muscular disease acquired through its $12 billion Avidity Biosciences deal.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVS","symbol_name":"诺华","start_time":0,"source_url":"","article_id":"1101227232","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101227232","pubTimestamp":1784641452,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 21, Novartis rose 3.76% in regular trading, trading at $154.1/share, with turnover of $79.53 million. The rally was driven by the company's Q2 earnings release that significantly exceeded...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVS":"诺华"},"translate_title":"走势提醒|诺华常规交易上涨3.76%，第二季度盈利大幅超出预期，预示着增长复苏","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVS":1},"content_text":"On July 21, Novartis rose 3.76% in regular trading, trading at $154.1/share, with turnover of $79.53 million. The rally was driven by the company's Q2 earnings release that significantly exceeded market expectations.Novartis reported Q2 adjusted earnings per share of $2.41, beating the consensus estimate of $2.13 by approximately 13%. Net sales came in at $14.408 billion, surpassing the expected $14.0 billion. Notably, Q1 results had disappointed due to generic competition against its blockbuster heart drug Entresto, but strong performance from next-generation oncology drugs successfully offset the generic impact this quarter, signaling a return to growth trajectory.Additionally, Novartis CEO stated the company will continue pursuing acquisitions, particularly targeting deals under $2 billion while not ruling out larger transactions. The company also expects multiple key clinical data readouts in the second half, covering cardiology and multiple sclerosis, including del-desiran for muscular disease acquired through its $12 billion Avidity Biosciences deal.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101227232","isCrawlerRequest":true}